Telehealth Ketamine in California: Access, Laws, and What to Know

Telehealth ketamine in California is legal when prescribed under the same framework used nationwide. The state follows the federal Ryan Haight Online Pharmacy Consumer Protection Act, a federal law requiring a valid provider-patient relationship, typically established through a real-time audio-visual evaluation, before a prescriber can send a controlled substance prescription electronically, along with standard telehealth practice rules enforced by the Medical Board of California. Ketamine is a Schedule III controlled substance, a federal Controlled Substances Act category for drugs with an accepted medical use and moderate to low potential for physical dependence. California has not added ketamine-specific telehealth restrictions on top of these baseline rules, but prescribers must still document a clinical evaluation that meets ordinary standard-of-care requirements. Because federal telehealth flexibilities for controlled substances remain subject to ongoing DEA rulemaking, confirm current requirements with the Medical Board of California before scheduling care.

California has one of the broadest telehealth ketamine markets in the country. With close to 39 million residents and a large physician workforce, the state supports a competitive field of telehealth providers, an established compounding pharmacy sector, and telehealth laws that predate most other states' frameworks. Patients from the Bay Area to the Central Valley to rural northern counties can generally reach a licensed telehealth ketamine provider without traveling to a specialty clinic.

California's telehealth rules trace back to the Telehealth Advancement Act of 2011 (AB 415), later expanded by SB 1665. Together they allow a licensed provider to establish a patient relationship through telehealth without a prior in-person visit, as long as the standard of care is met. The Medical Board of California, the state agency that licenses and disciplines physicians, oversees telehealth practice for MDs, and the Osteopathic Medical Board of California does the same for DOs. Both boards treat telehealth as a legitimate mode of care delivery when documentation and clinical justification support the prescription.

Ketamine is a Schedule III controlled substance under both federal law and California Health and Safety Code Section 11056. Prescribers must hold an active California medical license and a DEA registration, and must check CURES, California's Controlled Substance Utilization Review and Evaluation System and the state's prescription drug monitoring program, before writing a controlled substance prescription. The Medical Board of California has taken enforcement action against providers who prescribed controlled substances without adequate evaluation, so documentation matters as much for a provider's compliance as for patient safety. Compare California's approach with other states in our state-by-state regulatory guide.

Provider availability is high across California. National telehealth ketamine platforms serve the state, and several are headquartered there, giving patients a wide selection of prescribers, including in rural and agricultural regions such as the Central Valley, the far north, the eastern Sierra, and desert communities, where in-person psychiatric specialists can be hours away. Even in Los Angeles and San Francisco, telehealth often means shorter wait times than in-person ketamine clinics. California's participation in the Interstate Medical Licensure Compact, an agreement that speeds license portability for physicians practicing across member states, adds to the pool of clinicians who can treat California patients.

California nurse practitioners who hold a 103 or 104 practice designation, license categories that permit independent practice after meeting state-defined experience and certification requirements, can independently prescribe Schedule III controlled substances such as ketamine under defined conditions. That means the prescriber on a telehealth visit may be a physician, a qualified nurse practitioner, or, depending on scope-of-practice rules, a physician assistant. Patients can confirm a specific prescriber's license and scope of practice through the Medical Board of California or the California Board of Registered Nursing. See our provider selection guide for questions to ask before booking a first visit.

California has one of the strongest compounding pharmacy sectors in the country. The California State Board of Pharmacy regulates both in-state and nonresident pharmacies under the state's Business and Professions Code and requires compliance with USP <795> and USP <797>, United States Pharmacopeia standards that govern non-sterile and sterile compounding practices. Pharmacies located outside California must hold a nonresident pharmacy license to ship compounded medications to California patients, and the board has conducted inspections and taken action against pharmacies found out of compliance. Proximity to major pharmacy distribution hubs means most compounded ketamine orders reach California patients within one to three business days, though patients in remote mountain or desert communities may see longer delivery windows.

California's telehealth parity law requires health plans to cover telehealth-delivered services on the same basis as in-person services, but that parity only applies to services a plan already covers. Compounded ketamine used off-label for psychiatric conditions is generally excluded from coverage by both private plans and Medi-Cal, California's Medicaid program. Medi-Cal may cover Spravato (esketamine), the FDA-approved nasal spray formulation of ketamine therapy, with prior authorization, and California is considered one of the more accommodating state Medicaid programs for FDA-approved esketamine when treatment-resistant depression criteria are met. Commercial insurance coverage for Spravato follows a similar pattern, while off-label compounded oral, sublingual, and intramuscular ketamine is typically self-pay regardless of insurer. Some plans will cover the telehealth consultation fee even when the medication itself is not, so it is worth asking a plan directly about prior authorization and visit coverage.

Out-of-pocket costs in California tend to run higher than the national average, reflecting the state's cost of living. Monthly medication costs typically range from $150-$350, and consultation fees range from $150-$300, with providers serving the Bay Area and Los Angeles metro sometimes charging more than those serving patients statewide. See our guide to insurance versus cash-pay ketamine costs for a broader breakdown.